Krynon, vaginal gel 90 mg/dose 1 dose 15 pcs

Progesterone is a hormone of the corpus luteum. It induces the transition of the uterine mucosa from the FSH-induced proliferation phase to the secretory phase. It reduces the excitability and contractility of the uterine muscles and fallopian tubes. Progesterone inhibits the secretion of hypothalamic release factors FSH and LH, inhibits the formation of gonadotropic hormones in the pituitary and inhibits ovulation. The progesterone in the form of a vaginal gel is incorporated into a polymeric delivery system that binds to the vaginal mucosa and guarantees a sustained release of the drug for at least 3 days.

Pharmacokinetics

Intake. When vaginal gel is administered at a dose containing 90 mg of progesterone, T< sub> max of the drug in the blood (11 ng/mL) is about 6 hours. T< sub>1/2 is 34-48 h.

Metabolism. Progesterone is metabolized mainly in the liver. Vaginal use significantly reduces the effect of first passage through the liver.

The major metabolite, 3α,5β-pregnandiol, is excreted in the urine.

Indications

Maintaining the luteal phase during the use of assisted reproduction methods
Secondary amenorrhea, dysfunctional uterine bleeding caused by progesterone deficiency
Hormone replacement therapy

Pharmacological effect

Progesterone is a hormone of the corpus luteum. Causes a transition of the uterine mucosa from the proliferation phase caused by FSH to the secretory phase. Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes. Progesterone inhibits the secretion of hypothalamic release factors of FSH and LH, inhibits the formation of gonadotropic hormones in the pituitary gland and inhibits ovulation. In Crinon®, progesterone in the form of a vaginal gel is included in a polymer delivery system that binds to the vaginal mucosa and ensures continuous release of the drug for at least 3 days.

Pharmacokinetics

Suction. When using vaginal gel in a dose containing 90 mg of progesterone, Tmax of the drug in the blood (11 ng/ml) is about 6 hours. T1/2 is 34–48 hours.

Metabolism. Progesterone is metabolized primarily in the liver. Vaginal administration significantly reduces the first-pass effect through the liver.

The main metabolite, 3α,5β-pregnanediol, is excreted in the urine.

Special instructions

Crinon contains sorbic acid, which can cause a local skin reaction (contact dermatitis).
During long-term treatment, regular gynecological examinations are necessary to exclude the possibility of developing endometrial hyperplasia.

In order to prevent the possibility of a “threatening” miscarriage when using Crinon, the level of human chorionic gonadotropin should be determined or an ultrasound examination should be performed. Use with caution in case of liver dysfunction. In the case of sudden bleeding, as in the case of irregular vaginal bleeding, a non-functional cause should be excluded. In case of vaginal bleeding of unknown etiology, appropriate examination should be carried out.

Since progestogens have the properties of retaining fluid in the body, patients with diseases such as epilepsy, migraine, asthma, cardiovascular failure, and renal impairment should be closely monitored.

Patients with a history of depression should be closely monitored and treatment should be interrupted if depression worsens.

A small number of patients receiving estrogen-progestogen therapy may experience decreased glucose tolerance. The mechanism of this disorder is not known. In this regard, patients suffering from diabetes mellitus should be closely monitored during treatment with progesterone.

Active ingredient

Progesterone

Composition

1 applicator contains:

Active substance:

progesterone – 90 mg;

Excipients:

glycerol,

light liquid paraffin,

hydrogenated palm oil glyceride,

carbomer 974Р,

sorbic acid,

polycarbophil,

sodium hydroxide,

purified water.

Pregnancy

Crinon should not be used during pregnancy, with the exception of use in early pregnancy during assisted reproduction methods.

Crinon should not be used during breastfeeding.

Contraindications

hypersensitivity to progesterone or other components of the drug;
vaginal bleeding of unknown etiology;
acute porphyria;
malignant tumors of the genital organs or mammary glands or suspicion of their presence;
acute thrombosis or thrombophlebitis, thrombroembolic diseases, acute cerebrovascular accident (including a history);
incomplete abortion;
breastfeeding period.

With caution: arterial hypertension, chronic renal failure, cardiovascular failure, diabetes mellitus, bronchial asthma, epilepsy, migraine, depression, hyperlipoproteinemia.

Side Effects

Headache, drowsiness, abdominal pain, breast tenderness.

Rarely – intermenstrual bleeding, irritation of the vaginal mucosa at the site of application.

Interaction

The use of Crinon together with other intravaginal agents is not recommended.

Storage conditions

At a temperature not higher than 25° C.

Shelf life

3 years.

Manufacturer

Dendron Brands Limited, UK